Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178723 | 0.92 | MRGPRX4 (0.38) | MRGPRX4ACHEMAPTKMT2AKDM4E | |
| SCHEMBL18182595 | 0.91 | MRGPRX4 (0.39) | MRGPRX4MAPTLMNANPC1ALDH1A1 | |
| SCHEMBL18182960 | 0.90 | PDCD1 (0.37) | MRGPRX4LMNAFFAR4 | |
| SCHEMBL18182041 | 0.90 | MRGPRX4 (0.40) | MRGPRX4ACHEKMT2AKDM4ELMNA | |
| SCHEMBL18156494 | 0.90 | ACHE (0.37) | MRGPRX4ACHEMAPTKMT2AKDM4E | |
| SCHEMBL18182006 | 0.90 | SLC22A12 (0.39) | MRGPRX4ACHEMAPTKMT2AKDM4E | |
| SCHEMBL18182264 | 0.90 | KMT2A (0.38) | MRGPRX4ACHEMAPTKMT2AKDM4E | |
| SCHEMBL18182028 | 0.90 | KMT2A (0.39) | MRGPRX4ACHEKMT2AKDM4ELMNA | |
| SCHEMBL18156317 | 0.90 | FFAR4 (0.38) | MRGPRX4ACHEMAPTKMT2AKDM4E | |
| SCHEMBL18178654 | 0.89 | MAPT (0.38) | MRGPRX4ACHEMAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MRGPRX4 167/4885ACHE 460/4885MAPT 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.